<DOC>
	<DOC>NCT02005484</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of Herceptin in patients with metastatic or advanced gastric cancer with disease progression during platinum-based or 5-fluoropyrimidine-based chemotherapy. The anticipated time on study treatment is until disease progression.</brief_summary>
	<brief_title>A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>adult patients 1875 years of age; metastatic or advanced gastric cancer; disease progression under or after 1 prior platinumbased or 5fluoropyrimidinebased chemotherapy for metastatic disease; &gt;=4 weeks from last platinumbased or fluoropyrimidinebased chemotherapy; &gt;=1 measurable lesion; HER2 overexpression (IHC [2+] or [3+]). concurrent chemotherapy or immunotherapy; brain or meningeal metastases; clinically significant cardiac disease, advanced pulmonary disease or severe dyspnoea; coexisting malignancies or malignancies diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ; women who are pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>